Annual report pursuant to Section 13 and 15(d)

Commitment and Contingencies - Additional Information (Details)

v3.24.1
Commitment and Contingencies - Additional Information (Details)
12 Months Ended
Sep. 08, 2020
Debtinstrument
Jan. 21, 2020
Debtinstrument
Dec. 31, 2023
USD ($)
UsdRln
Nov. 18, 2015
USD ($)
Royalty-Linked Notes        
Other Commitments [Line Items]        
Debt instrument outstanding portion | UsdRln     0.04  
Debt instrument maturity date     Dec. 31, 2045  
Debt instrument price per unit     $ 160  
Debt instrument, aggregate potential payment capped rate     4,000  
Royalty-Linked Notes | Private Placement        
Other Commitments [Line Items]        
Number of debt instruments within each notes | Debtinstrument   2,579,400    
Royalty-Linked Notes | Rights Offering        
Other Commitments [Line Items]        
Number of debt instruments within each notes | Debtinstrument 11,000      
Pfizer License Agreement | Minimum        
Other Commitments [Line Items]        
Potential future regulatory milestone and sales milestone payments upon achievement of net sales       $ 250,000,000
Pfizer License Agreement | Maximum        
Other Commitments [Line Items]        
Potential future regulatory milestone and sales milestone payments upon achievement of net sales       $ 1,000,000,000